Search Within

David Hyman

  1. "Jason Konner"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (7)
Groups
  1. Department of Medicine (15)
  2. Early Drug Development Service (15)
  3. GDMT, Medicine (15)
  4. Gynecologic Medicine Service (15)
  5. Gynecology Disease Management Team (15)
  6. Solid Tumor Oncology Division (15)

More Groups

People
  1. Jason Konner (15)
  2. Carol Aghajanian (12)
  3. Rachel Grisham (11)
  4. Martee Hensley (8)
  5. Paul Sabbatini (8)
  6. Roisin O'Cearbhaill (8)

More People

Years
  1. 2019 (2)
  2. 2018 (3)
  3. 2017 (4)
  4. 2015 (2)
  5. 2013 (1)
  6. 2012 (2)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Clinical Cancer Research (4)
  3. International Journal of Gynecological Cancer (2)
  4. Blood (1)
  5. Cancer Chemotherapy and Pharmacology (1)
  6. Gynecologic Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. American Association for Cancer Research (4)
  3. Lippincott Williams & Wilkins (2)
  4. Springer (2)
  5. American Society of Hematology (1)
  6. Elsevier B.V. (1)

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer
    Meeting Abstract

    Friedman, C. F.; Donoghue, M.; Vivek, M.; Aghajanian, C.; Abu-Rustum, N.; Cadoo, K. A.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Kyi, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Clinical utility of prospective molecular characterization in advanced endometrial cancer
    Journal Article

    Soumerai, T. E.; Donoghue, M. T. A.; Bandlamudi, C.; Srinivasan, P.; Chang, M. T.; Zamarin, D.; Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Tew, W. P.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer
    Journal Article

    LaVigne, K.; Hyman, D. M.; Zhou, Q. C.; Iasonos, A.; Tew, W. P.; Aghajanian, C.; Makker, V.; Hensley, M. L.; Konner, J.; Grisham, R. N.; more...
    International Journal of Gynecological Cancer (2018)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Somatic mutations in homologous recombination pathway genes in ovarian cancer
    Meeting Abstract

    Aghajanian, C.; DeLair, D.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Makker, V.; O'Cearbhaill, R. E.; Sabbatini, P.; Soumerai, T.; Charen, A. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer
    Journal Article

    Weigelt, B.; Comino-MeĢndez, I.; de Bruijn, I.; Tian, L.; Meisel, J. L.; Garcia-Murillas, I.; Fribbens, C.; Cutts, R.; Martelotto, L. G.; Ng, C. K. Y.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer
    Meeting Abstract

    O'Cearbhaill, R. E.; Hyman, D. M.; Tew, W. P.; Iasonos, A.; Cangemi, N. A.; Aghajanian, C.; Bell-Mcguinn, K. M.; Makker, V.; Hensley, M. L.; Konner, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save